Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.57 |
| ▸ | PDE4A | P27815 | 11/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13111720 | 0.94 | RECQL (0.61) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| Nitrous Acid SCHEMBL7214855 | 0.92 | PDE4B (0.54) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL23717328 | 0.87 | RECQL (0.53) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL2958828 | 0.86 | RECQL (0.60) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL5309679 | 0.86 | PDE4B (0.56) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL2956981 | 0.86 | CSNK2A1 (0.66) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL5703607 | 0.86 | PDE4B (0.56) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL7333965 | 0.85 | PDE4B (0.56) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL1157799 | 0.84 | POLB (0.55) | PDE4BPDE4ARECQLPDE4CPDE4D | |
| SCHEMBL13317191 | 0.83 | RECQL (0.61) | PDE4BPDE4ARECQLPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016073903-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| EP-1308440-B1 | PIPERIDINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | ROSKAMP RESEARCH LLC (US) | 2008-03-06 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-6372770-B1 | TREATING A MAMMAL SUFFERING FROM A DISEASE STATE SELECTED FROM THE GROUP CONSISTING OF ASTHMA, ALLERGIES, INFLAMMATION, DEPRESSION, DEMENTIA, ATOPIC DISEASES, RHINITIS AND DISEASE STATES ASSOCIATED WITH ABNORMALLY HIGH PHYSIOLOGICAL LEVELS OF | EURO-CELTIQUE, S.A. | 2002-04-16 | — | — | US | disclosed |
| EP-0785927-A4 | NOVEL BENZOXAZOLES | EURO CELTIQUE SA (LU) | 1997-12-29 | — | — | EP | disclosed |
| EP-0785927-A1 | NOVEL BENZOXAZOLES | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011917-A1 | NOVEL BENZOXAZOLES | EURO-CELTIQUE, S.A. (LU) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | PDE4B 1989/4885PDE4A 2010/4885RECQL 1595/4885 |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | APP, PSEN1, PSEN2 | PDE4B 704/4885PDE4A 621/4885RECQL 2813/4885 |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 1/4885RECQL 1661/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 1/4885RECQL 1661/4885 |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PDE4B 992/4885PDE4A 917/4885RECQL 3052/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PDE4B 992/4885PDE4A 917/4885RECQL 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.